Infection prevention in the operating room anesthesia work area

L. Silvia Munoz-Price MD, PhD¹, Andrew Bowdle MD, PhD², B. Lynn Johnston MD³, Gonzalo Bearman MD, MPH⁴, Bernard C. Camins MD, MSc⁵, E. Patchen Dellinger MD², Marjorie A. Geisz-Everson PhD, CRNA⁶, Galit Holzmann-Pazgal MD⁷, Rekha Murthy MD⁸, David Pegues MD⁹, Richard C. Prielipp MD, MBA, FCCM¹⁰, Zachary A. Rubin MD¹¹, Joshua Schaffzin MD, PhD¹², Deborah Yokoe MD, MPH¹³ and David J. Birnbach MD, MPH¹⁴

¹Froedtert & the Medical College of Wisconsin, Milwaukee, Wisconsin, ²University of Washington, Seattle, Washington, ³Dalhousie University, Halifax, Nova Scotia, ⁴Virginia Commonwealth University School of Medicine, Richmond, Virginia, ⁵University of Alabama at Birmingham, Birmingham, Alabama, ⁶University of Southern Mississippi, Hattiesburg, Mississippi, ⁷Baylor College of Medicine, Houston, Texas, ⁸Cedars-Sinai Medical Center, Los Angeles, California, ⁹University of Pennsylvania, Philadelphia, Pennsylvania, ¹⁰University of Minnesota, Minneapolis, Minnesota, ¹¹David Geffen School of Medicine at UCLA, Los Angeles, California, ¹²Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio, ¹³University of California San Francisco School of Medicine, San Francisco, California and ¹⁴University of Miami Miller School of Medicine, Miami, Florida

(Received 15 October 2018; accepted 19 October 2018)

Purpose

The potential for clinically significant microbial cross transmission in the intraoperative environment poses a threat to patient safety. A growing body of literature has shown contamination in the anesthesia work area, including the anesthesia medical work cart, stopcocks, laryngeal masks and laryngoscope blades, touchscreens, and keyboards, as well as on providers’ hands, resulting in transmissions, healthcare-associated infections, and increased risk of patient mortality.

The authors acknowledge that the operating room (OR) is a challenging environment in which to affect ideal infection prevention and control practices. In addition, infection prevention and control policies specific to anesthesia care in the OR are not universal; audits of infection prevention practices are not routine; and consequently, providers may not have clarity on expected practices and behaviors. Studies have reported problematic practices by anesthesia providers, including use of multiple-dose vials for >1 patient, <100% use of gloves for airway management, failure to perform hand hygiene (HH) after removing gloves, and entry into anesthesia cart drawers without performance of HH. This guidance provides recommendations specific to the anesthesia work area to improve infection prevention through HH, environmental disinfection, and implementation of effective improvement efforts.

Furthermore, SHEA acknowledges significant challenges to implementing the array of infection prevention and control recommendations to affect OR culture in general, and the work flow of anesthesia providers in particular. Facility administrators will need to actively collaborate with anesthesia department leaders to build an implementation plan that is timely, comprehensive, and multidisciplinary, and that will allocate hospital resources to educate healthcare personnel and to acquire new infection prevention and control components (eg, single-use laryngoscopes). Facilities should consider this guidance document in revisions of their anesthesia OR policies.

This guidance builds on the foundational premise that all facilities where anesthesia services are delivered have formal infection prevention and control programs. Essential elements of these programs include, but are not limited to, policies and procedures for HH, safe preparation and delivery of intravenous medications, and environmental cleaning and disinfection. All individuals involved in these procedures require training appropriate to their tasks, as well as regular skills assessments.

Authors

The writing panel (the authors) consists of current and past members of the SHEA Guidelines Committee and representatives of organizations that partnered with SHEA to write this document: Dr. David J. Birnbach, American Society of Anesthesiologists (ASA); Dr. Richard C. Prielipp, Anesthesia Patient Safety Foundation (APSF); and Dr. Marjorie Geisz-Everson, American Association of Nurse Anesthetists (AANA). All panel members served as volunteers.

Intended Use

SHEA develops expert guidance documents (EGs) for topics of relatively narrow scope that lack the level of evidence required for a formal guideline developed using the GRADE or a similar systematic methodology but are important in provision of safe, effective healthcare. As such, systematic grading of the evidence level is not provided for individual recommendations. Each EG is based on a synthesis of limited evidence, theoretical rationale,
current practices, practical considerations, writing group opinion, and consideration of potential harm where applicable.

No EG can anticipate all clinical situations, and this guidance document is not meant to be a substitute for individual clinical judgment by qualified professionals.

**Methods**

**Document development**

This expert guidance document follows the process outlined in the “Handbook for SHEA-Sponsored Guidelines and Expert Guidance Documents.” The topic was among those proposed and selected by the SHEA Guidelines Committee (GLC). The subsequent manuscript proposal developed by the GLC was approved by the SHEA Publications Committee and the SHEA Board of Trustees.

The writing panel developed PICO-style (population, intervention, control, and outcomes) questions based on themes identified by the panel. These questions were used in the development of search terms (medical subject heading [MeSH] and text word), and both the questions and search terms were voted on by the panel until unanimous approval was achieved. The writing panel identified the period from which articles would be collected as January 1, 1990, to June 30, 2016. Only English language articles were included. The lists of articles generated from the searches were reviewed by a primary reviewer and secondary reviewer for inclusion. For this topic, the authors conducted 2 surveys of the SHEA Research Network (SRN) and subsets of the American Association of Nurse Anesthetists (AANA), the American Society of Anesthesiologists (ASA), and the American Academy of Nurse Anesthetists (AORN), and the Anesthesia Patient Safety Foundation (APSF). The writing panel developed PICO-style (population, intervention, control, and outcomes) questions based on themes identified by the panel. These questions were used in the development of search terms (medical subject heading [MeSH] and text word), and both the questions and search terms were voted on by the panel until unanimous approval was achieved. The writing panel identified the period from which articles would be collected as January 1, 1990, to June 30, 2016. Only English language articles were included. The lists of articles generated from the searches were reviewed by a primary reviewer and secondary reviewer for inclusion. For this topic, the authors conducted 2 surveys of the SHEA Research Network (SRN) and subsets of the American Association of Nurse Anesthetists (AANA), the American Society of Anesthesiologists (ASA), and the American Academy of Anesthesiologist Assistants (AAAA) membership.

SHEA EGs are developed with a formalized process for reaching expert consensus. Recommendations are listed with rationale statements that consider relevant evidence as well as the consensus of the group. Consensus around recommendations and rationale was determined via an anonymous comment period. For this EG, full consensus was achieved.

**Review and endorsement**

The document was reviewed and approved by the SHEA Guidelines Committee and the SHEA Publications Committee and was endorsed by the SHEA Board of Trustees, the AAAA, the Association for periOperative Registered Nurses (AORN), and the Anesthesia Patient Safety Foundation (APSF). The ASA provided a letter of support with qualifications (Appendix 1).

**Surveys**

**SHEA Research Network (SRN)**

In December 2016, a survey was sent to SHEA Research Network (SRN) members to gather information on infection prevention and control policies and practices for anesthesia providers in the OR setting. In total, 59 individual healthcare epidemiologists at their healthcare institutions responded (43 United States members and 16 international members) from the 130 invited to participate, for a response rate of 45.8%.

The minority of SRN respondents (35.6%) reported having infection prevention and control policies specific to anesthesia practice in the OR, with international respondents (10 of 16) more likely than US respondents (11 of 43) to have such policies ($P = .008$). For respondents answering that there were no (n = 35) or unknown (n = 7) policies specific to anesthesia, 97.5% reported the expectation that anesthesia provider practice in the OR would be in compliance with institutional policies (supplementary Table 1).

Only 3 respondents reported that their facility has a policy that allows anesthesia providers to perform HH on gloved hands as an alternative to changing gloves followed by HH, and in one instance this was a written policy. Also 7 respondents answered that anesthesia providers are allowed to wear 2 sets of gloves during airway management and to remove the outer glove without performing additional HH, although in no instance was this a written policy. Among respondents who were aware of their facility’s practices, 34.9% and 21.6% of institutions routinely used single-use laryngoscopes or video-laryngoscopes, respectively. Generally, facilities audited anesthesia providers’ infection prevention and control practices in the OR when there was a concern about practices (52.5%), although 13 respondents (22%) reported a monthly audit. Only 4 facilities (6.8%) never conducted audits (supplementary Table 2).

**Survey to members of ASA, AANA, and AAAA**

The panel sent a survey focused on practices that providers follow while giving care in the OR setting to 3 groups of anesthesia providers in March 2017: 5,000 members of ASA; 5,000 members of AANA, and 1,761 members of the AAAA. We received responses from 396 physicians (8%; 113 in academic practice, 277 in private practice, 6 in training), 246 nurse anesthetists (5%; 236 certified, 10 in training), and 70 anesthesiologist assistants (4%; 56 certified, 14 in training). The majority had >10 years in practice (0–10 years, 27.3%; 11–30 years, 49.4%; >30 years, 23.3%). Two-thirds of respondents reported having infection prevention and control guidelines specific for anesthesia services in their institution (supplementary Table 3). Alcohol-based hand rub (ABHR) was generally readily available within the anesthesia work area (always or usually: 93.8%) and was located at entry points to every OR (always or usually, 92.3%). Respondents identified the following barriers to HH: lack of time in emergency situations (58.3%), lack of time in general (44.2%), skin factors (35.8%), HH equipment not easily accessible (27%), and lack of support from OR personnel for HH-related workflow interruptions (15.5%) (supplementary Table 4).

Anesthesia providers identified several barrier precautions used for inserting central lines: mask (94.4%), sterile gloves (93.8%), gown (88%), cap (91.6%), and full drape (79.2%). The practice was different for placing arterial lines, with providers using all barrier elements less frequently: masks, 82%; sterile gloves, 74.2%; gown, 10.9%; cap, 76.8%; full drape, 3.7%). Almost half did not use a drape (48.1%).

Institutions provided feedback variably on their departments’ adherence to HH (never, 40.9%; every 6–12 months, 34.9%; quarterly, 24.2%) and other infection prevention and control practices and procedures (never, 42.3%; every 6–12 months, 36.8%; quarterly, 20.9%).

**Discussion**

Given the low response rate from anesthesia providers, it is difficult to determine how generalizable findings are to all
institutions and all anesthesia providers. If respondents represent providers who are most interested in following infection prevention and control practices, these results likely overestimate adherence with infection prevention and control in the OR setting; nonetheless, some conclusions may be drawn:

1. Infection prevention and control policies specific to anesthesia care in the OR are not universal in US healthcare facilities.
2. Audits of infection prevention and control practices are not routine.
3. Not all anesthesia work areas are cleaned and disinfected between every patient, and the anesthesia cart is an item of risk for cross contamination.
4. Certain anesthesia provider practices remain problematic, especially the use of multiple-dose vials for >1 patient, <100% use of gloves for airway management, lack of HH after removing gloves, and entry into anesthesia cart drawers without HH.

The authors acknowledge that the OR is a challenging environment in which to affect ideal infection prevention and control practices, but we note the opportunity for improvement.

**Guidance Statement**

**Hand hygiene**

**Which activities in anesthesia care should always result in hand hygiene (HH)?**

**Recommendation:** HH ideally should be performed according to the WHO 5 Moments for Hand Hygiene. The authors recommend that HH be performed at the minimum before aseptic tasks (e.g., inserting central venous catheters, inserting arterial catheters, drawing medications, spiking IV bags); after removing gloves; when hands are soiled or contaminated (e.g., oropharyngeal secretions); before touching the contents of the anesthesia cart; and when entering and exiting the OR (even after removing gloves).

**Rationale:** Previous observational studies have reported that if the WHO 5 Moments for Hand Hygiene is used as the standard, the indications for HH among anesthesia providers in the OR can be as high as 54 per hour, leading to nonadherence rates of 83%. These findings have led some investigators to conclude that applying the WHO 5 Moments in the anesthesia work area, especially during induction, is logistically unfeasible. Muñoz-Price et al showed that increasing access to ABHR led to an increase in the number of times HH was performed by anesthesia staff during a surgical procedure. Another study suggests that wearable ABHR dispensers improve HH adherence among anesthesia providers. Koff et al showed that the use of a wearable ABHR dispenser capable of recording HH events decreased the contamination rate of intravenous tubing in the operating room (OR). In a multisite randomized controlled trial, Koff et al also showed that providing wearable dispensers to anesthesia providers resulted in an 8-fold increase in the number of times HH was performed compared to rooms where only wall-mounted ABHR dispensers were available.

**Should providers wear double gloves during airway management and discard the outer glove immediately after airway manipulation?**

**Recommendation:** To reduce risk of contamination in the OR, providers should consider wearing double gloves during airway management and should remove the outer gloves immediately after airway manipulation. As soon as possible, providers should remove the inner gloves and perform HH.

**Rationale:** Anesthesia providers’ hands may become contaminated with upper-airway secretions while providing airway management and endotracheal intubation. Providers may not be able to perform HH during this time, and cross contamination of the anesthesia work area can occur. The literature search identified 2 randomized trials and 1 anecdotal report related to the strategy of using double gloves to decrease contamination in the OR.

**Where should facilities locate alcohol-based hand rub (ABHR) dispensers in the OR?**

**Recommendation:** The authors recommend that facilities locate ABHR dispensers at the entrances to ORs and near anesthesia providers inside the OR in order to promote frequent HH. Several studies have demonstrated that wearable ABHR dispensers with audible reminders increase the frequency of HH as well as the potential to decrease the incidence of HAI. While the specific wearable devices used in these studies are not currently available, the authors recommend that facilities consider suitable wearable ABHR dispensers with automatic reminders when commercially available. ABHR dispensers should be located in accordance with applicable national and local fire safety standards and codes. Additionally, the authors recommend that the facility delegate the filling of the ABHR dispensers to designated personnel and regularly ensure compliance with this practice.

**Rationale:** Locating ABHR dispensers at entrances to ORs facilitates the recommended practice of performing HH before entry and after exiting the room, and locating ABHR dispensers on the anesthesia machine has been associated with a modest increase in the frequency of HH. Researchers in one study found that the use of a wearable ABHR dispenser with an audible reminder resulted in a significant increase in HH and reduction in anesthesia work area contamination, IV tubing contamination, and healthcare-associated infection; however, a subsequent similar study found an increase in the rate of HH but no effect on the rate of healthcare-associated infection.

A variety of local and national fire-prevention standards and codes may restrict the placement of ABHR dispensers on top of the anesthesia machine. For example, the National Fire Protection Association (NFPA) 101: Life Safety Code stipulates the maximum allowable volume of an individual ABHR dispenser to be 1.2 L and requires that dispensers be separated horizontally by at least 122 cm (48 inches), and that dispensers be at least 2.5 cm
Can the anesthesia provider apply ABHR on gloves that are being worn during a case, rather than removing the gloves, performing HH, and then replacing a new set of gloves if contaminated?

**Recommendation:** Changing gloves with HH between doffing and donning is the preferred method of disinfection. Current data are inadequate for the authors to either support or discourage the procedure of using ABHR on gloved hands or to determine whether application of foam or gel affects glove integrity. However, application of ABHR to gloved hands might be better than to not perform any HH when doffing and donning are not feasible.

**Rationale:** The clinical practice of disinfecting latex or nitrile disposable gloves with ABHR is an interesting but currently uncommon practice (supplementary Table 4). Application of foam or gel may have unknown or unintended consequences on glove integrity; however, during the Ebola outbreak in 2014, the Centers for Disease Control and Prevention (CDC) published detailed guidance (revised in 2015) recommending that ABHR be used for disinfecting the gloves at multiple times during doffing of the personal protective equipment. A recent paper demonstrated that multiple ethanol-based hand-rub administrations did not show observable signs of material degradation with nitrile and latex gloves; however, the study did not test every available glove material. A study of ABHR to gloves at multiple times during doffing of the personal protective equipment demonstrated that multiple ethanol-based hand-rub administrations did not show observable signs of material degradation with nitrile and latex gloves; however, the study did not test every available glove material. A study of ABHR to gloves at multiple times during doffing of the personal protective equipment demonstrated that multiple ethanol-based hand-rub administrations did not show observable signs of material degradation with nitrile and latex gloves. Nevertheless, the authors believe that application of ABHR to gloved hands could produce the unintended consequence of making the identification of clean hands more difficult (eg, “Are these gloves contaminated or was ABHR applied?”). Nevertheless, the authors believe that application of ABHR to gloves in the anesthesia workplace is worthy of consideration and further investigation. The CDC and WHO guidelines recommend removing gloves before performing HH as standard practice; however, given the frequency of HH opportunities in the perioperative setting, evaluation of the effectiveness and feasibility of application of ABHR to gloves in the anesthesia workplace as an alternative practice merits further investigation. Additionally, the authors encourage glove manufacturers to perform studies to indicate whether and how many ABHR applications can occur while still maintaining the glove’s integrity.

**Environmental disinfection**

**Should reusable laryngoscopes or video-laryngoscopes be replaced with single-use laryngoscopes/video-laryngoscopes?**

**Recommendation:** The authors recommend that facilities ensure that standard direct laryngoscope or video-laryngoscope reusable handles and blades undergo high-level disinfection (at the minimum) or sterilization prior to use, or that reusable laryngoscopes are replaced with single-use standard direct laryngoscopes or video-laryngoscopes. Clean blades and handles should be stored in packaging appropriate for semicritical items designated for “high-level” disinfection.

**Rationale:** Researchers have found bacteria, blood, and lymphoid tissue contamination of laryngoscope blades and handles following low-level decontamination. Infectious disease outbreaks have been associated with contaminated laryngoscopes. Laryngoscopes are considered “semicritical” devices and therefore should be subjected to high-level decontamination (at the minimum) or sterilization. The Joint Commission and other regulators require that standard direct laryngoscope reusable blades be subject to high level decontamination (at the minimum) or sterilization and that blades be packaged to maintain decontamination until just prior to use. Optimal processing of laryngoscope handles has been subject to some controversy. Many reusable laryngoscope handles require disassembly prior to high-level decontamination or sterilization, making the cleaning process potentially costly.

The authors recommend that handles that are not able to undergo high-level disinfection according to manufacturer’s instructions should not be used. The State of California Health and Human Services Agency Department of Health Services recommends high-level decontamination of laryngoscope handles. A study of laryngoscope handles cleaned with bactericidal wipes containing either 70% alcohol and 2% chlorhexidine or coco alkyl dimethyl benzyl ammonium chloride found that common bacteria were effectively eliminated; however, the authors point out that C. difficile and norovirus would not be expected to be eliminated by this treatment. They recommend autoclaving laryngoscope handles at risk for the presence of C. difficile and also on a routine, monthly basis. Single-use laryngoscopes have evolved considerably in recent years. Their performance may be comparable to reusable laryngoscopes, and their cost per use may be less than reusable laryngoscopes if the costs of high-level decontamination of reusable laryngoscopes are considered. Environmental issues pertaining to single-use laryngoscopes are addressed by some manufacturers with recycling programs for their products.

Although the authors did not conduct a literature search specific to supraglottic airway masks, they note the plausibility of residual contamination of these masks and suggest that facilities consider applying the same principles when deciding between reusable and single-use supraglottic airway masks.

**Should anesthesia machines be partially or completely covered with disposable covers to prevent contamination?**

**Recommendation:** Current data are inadequate for the authors to make recommendations regarding the use of disposable covers to prevent contamination of anesthesia machines. **Rationale:** Although several studies have demonstrated the potential for contamination of anesthesia equipment and workspaces and possible transmission of a variety of microorganisms within the anesthesia environment, the authors did not identify studies that evaluated the impact of equipment covers on the level of environmental contamination or patient infection risk. However, they suggest that facilities consider using disposable covers given the plausible reduction in contamination and facilitation of cleaning and disinfection of anesthesia machines.

---

22Items directly attached to instruments that contact mucous membranes, such as the handles of rigid laryngoscopes, should be considered semicritical instruments. **25**

---
When ORs are prepared between uses, what cleaning and disinfection of the anesthesia machine and anesthesia work area should take place?

**Recommendation:** To reduce the bioburden of organisms and the risk of transmitting these organisms to patients, the facility should clean and disinfect high-touch surfaces on the anesthesia machine and anesthesia work area between OR uses with an EPA-approved hospital disinfectant that is compatible with the equipment and surfaces based on the manufacturers’ instruction for use. Because of challenges in consistent cleaning and disinfection between cases of the anesthesia machine and anesthesia work area, the authors suggest prioritizing high-touch surfaces. In addition, the authors suggest evaluating strategies aimed at improving the ability to clean these surfaces (eg, disposable covers, re-engineering of work surfaces).

**Rationale:** A number of studies have demonstrated that anesthesia machines and work areas can become contaminated with a variety of potentially pathogenic microbes, and that these organisms may be transmitted to patients through direct contact with contaminated equipment, hands of anesthesia providers, or contaminated medications. However, few studies have evaluated specific cleaning and disinfection products or practices specific to the anesthesia work area.

The anesthesia work area, including the anesthesia machine, computer keyboard, monitor and mouse, reusable patient monitoring equipment, anesthesia cart, and ancillary equipment (such as ultrasound machines) are physically complex and are not primarily designed and engineered to facilitate efficient and thorough cleaning. The focus on expedited OR turnover within 10–15 minutes adds to the challenge of adequate cleaning. In the future, the authors encourage engineers and manufacturers to work with human factors experts to redesign the various components of the anesthesia work area to solve this problem. The authors suggest that anesthesia machine covers may be part of the solution, but evidence is lacking to endorse their use (see the preceding recommendation).

While awaiting evidence-based guidance, the authors recommend that the facility prioritize cleaning of the specific components that are most likely to be contaminated. Monitoring equipment such as reusable blood pressure cuffs, pulse oximeter probes, electrocardiogram (ECG) leads, twitch monitor leads and sensors, and cables that are in physical contact with patients should receive high priority for thorough cleaning (single-use monitoring sensors may be useful for reducing the cleaning burden). The anesthesia machine work surface, gas flow controls, vaporizer dials, adjustable pressure limiting valve (APL), IV stands and fluid warmers, supply cart, and computer keyboard and mouse, are also examples of components that are particularly likely to be contaminated.

**Should injection ports used by anesthesia providers in the OR be covered with isopropyl alcohol-containing caps? Should injection ports—without alcohol-containing caps—used by anesthesia providers in the OR be scrubbed with alcohol before each use?**

**Recommendation:** Anesthesia providers should only use disinfected ports for intravenous access. Ports may be disinfected either by scrubbing the port with a sterile alcohol-based disinfectant before each use immediately prior to each use or using sterile isopropyl alcohol containing caps that cover ports continuously. Prior to use, isopropyl alcohol–containing caps should cover the port for the minimum time recommended by the manufacturer. Ports should be properly disinfected prior to each individual drug injection or at the beginning of a rapid succession of injections, such as during induction of anesthesia. The authors recommend that providers consider using isopropyl alcohol containing caps, which, when in place for the recommended period, make ports immediately available for use at all times. Stopcocks should have closed injection ports installed to convert them into “closed ports,” or they should be covered with sterile caps.

**Rationale:** Peripheral intravenous tubing stopcocks and injection ports that are used for medication administration frequently become contaminated with potentially pathogenic bacteria during intraoperative use. Lower rates of provider HH, higher numbers of intravenous medications, and greater numbers of hub interactions increase the probability of injection port contamination. Although the literature does not provide direct evidence of clinical benefit in anesthesia practice, moderate- to high-quality evidence exists that disinfecting catheter hubs, needless connectors, and injection ports with a sterile alcohol-containing disinfectant reduces the risk of central-line–associated bloodstream infection (CLABSI). Optimally, the authors recommend disinfection of injection ports to be performed before each medication injection, consistent with recommendations in other patient care settings; however, published studies do not address the optimal frequency of injection port disinfection and the comparative effectiveness of alcohol-containing caps and alcohol wipes in anesthesia practice, and the authors acknowledge that the act of disinfecting injection ports for 10–15 seconds followed by a drying time can be challenging in anesthesia practice, particularly during induction and emergence of anesthesia. For this reason, compared to alcohol wipes, passive disinfection using sterile alcohol-containing caps offers visual assurance of hub disinfection and may assist facilities in improving and monitoring compliance with this best practice.

**When anesthesia drugs are drawn at the point of care should vials be scrubbed with alcohol prior to puncture?**

**Recommendation:** Anesthesia providers should wipe medication vials’ rubber stoppers and necks of ampules with 70% alcohol prior to vial access and medication withdrawal.

**Rationale:** The caps of anesthesia medications are not sterile; therefore, it should be standard practice to disinfect the rubber stoppers and neck of ampules prior to each use. A study in New Zealand observed 10 anesthesia teams during 20 simulated cases. None of the anesthesiologists disinfected the vial septa prior to drawing intravascular solutions, and the anesthesia teams said they believed this procedure was in compliance with infection prevention and control practices. These researchers isolated microorganisms from 5 of 38 collection bags (13%), 6 of 17 needles (35%), and 10 of 197 syringes (5%).

**Which intravenous catheters should be placed with full barrier precautions?**

**Recommendation:** All central venous catheters (CVCs) and axillary and femoral arterial lines should be placed with full maximal sterile barrier precautions. Full maximal sterile barrier precautions include wearing mask, cap, sterile gown, and sterile gloves and using a large sterile drape during insertion. Peripheral arterial lines (eg, radial, brachial, or dorsalis pedis arterial lines) should be
placed with a minimum of a cap, mask, sterile gloves, and a small sterile fenestrated drape.

**Rationale:** The authors based this recommendation on the Compendium of Strategies to Prevent Bloodstream Infections in Acute Care Hospitals and the 2011 Healthcare Infection Control Practices Advisory Committee (HICPAC) guideline, which identify the following maximal sterile barrier precautions for CVC and axillary and femoral arterial line insertion:

1. All healthcare personnel involved in the catheter insertion procedure should wear mask, cap, sterile gown, and sterile gloves.
2. The provider should cover the patient with a large (“full body”) sterile drape during catheter insertion.

The provider should also follow these measures when exchanging a catheter over a guidewire. Placement of other arterial lines should follow the HICPAC recommendations to use a minimum of a cover, mask, sterile gloves, and a small sterile fenestrated drape. As with other standard-of-care practices, in emergency situations providers should weigh other safety considerations.

**Should providers always recap a medication syringe after giving a portion of the syringe contents to the patient if the syringe and medication may be used again on that patient?**

**Recommendation:** To reduce the risk of bacterial contamination of the syringe and syringe contents, the authors recommend that anesthesia providers cap needless syringes that will be used to administer multiple doses of a drug to the same patient after each administered dose. Needleless syringes should be capped with a sterile cap that completely covers the Luer connector on the syringe.

**Rationale:** Bacterial contamination of medication syringes can occur during anesthesia practice, most commonly with skin microorganisms. Higher rates of medication contamination have been associated with emergency procedures, compared to elective surgical procedures. Low provider HH, lack of injection port disinfection, and contact with nonsterile equipment may increase the risk of intraoperative contamination of syringe contents when used to administer multiple doses of medication to the same patient. Although research has not assessed the effectiveness of capping medication syringes on reducing rates of medication contamination, it is plausible that capping medication syringes will reduce the risk of inadvertent contamination of the syringe and contents from the hands or work space of the anesthesia provider. The authors do not recommend recapping needless needles, which is highly discouraged due to the associated occupational hazards.

**What is the expiration time for sterile injectable drugs and intravenous solutions prepared by anesthesia providers?**

**Recommendation:** Provider-prepared sterile injectable drugs (eg, a drug drawn from a vial into a syringe) are more likely to be subject to contamination than drugs prepared in an ISO Class 5 setting, such as a pharmacy; therefore, provider-prepared sterile injectable drugs should be used as soon as practicable following preparation. The package inserts for propofol that contain a preservative typically specify that the use of propofol should commence within 12 hours of preparation. At the time of this publication, United States Pharmacopeia (USP) Chapter 797 recommends that the use of provider-prepared sterile injectable drugs commence within 1 hour of preparation; however, a draft revision of USP General Chapter 797 suggests that a drug from a single dose vial punctured or entered in environments with air less clean than ISO class 5 may be used until the end of a case. If available, commercially prefilled syringes or syringes prepared by the hospital pharmacy in an ISO class 5 setting have a relatively long “beyond use date.”

**Rationale:** The USP 797 generally is considered the applicable authority for the compounding of sterile injectable solutions and drugs. At the time of this publication, USP 797 states that the use of compounded sterile provider-prepared products outside of an
ISO class 5 setting (eg, a pharmacy IV room) be for “immediate use” only, commencing within 1 hour of preparation and interprets “compounding” as including drawing medications from vials into syringes. Scientific literature is sparse pertaining to a "immediate use" setting. To the best of our knowledge, the “1-hour limit” from USP 797 is based on the underlying principle that drugs prepared outside of a properly regulated pharmacy IV “clean room” are more likely to become contaminated, and bacterial counts may increase over time. Austin et al performed a systematic review of the literature and found a significantly higher frequency of contamination of doses prepared in clinical than in 10 pharmaceutical environments (3.7% vs 0.5%; P = .007). A draft of the revision of USP Chapter 797 released in July 2018 contains language suggesting that provider-prepared drugs could be used until “the end of a case.” This draft is subject to change and will not be finalized until late 2019.

Because no reliable method exists for knowing with certainty whether the drugs or solutions have been used, the authors suggest designated healthcare personnel discard provider-prepared sterile injectable drugs and intravenous solutions at the end of each case, whether used or not. If the drugs or solutions have been used, they may be contaminated and subsequent use for another patient may result in transmission of organisms to that patient.

The facility may consider returning to stock unused commercial prefilled syringes, which have not passed their “beyond use” date, have intact security locking caps, and have been present in the anesthesia work area during a case; however, consideration should be given to the possibility that the external surface of such syringes may become contaminated during a case and pose an infection risk if reused for another case.

In addition to USP 797, the facility may consider the advice of other authorities, which may be at variance with the 1-hour limit recommended by USP 797. For example, The Joint Commission’s recommendations for syringe labeling do not require labeling provider-prepared injectable drugs for “immediate use” with a date and time of expiration unless the expiration occurs within 24 hours of preparation, suggesting that “immediate use” may extend beyond 1 hour. The Food and Drug Administration (FDA) “package insert” for propofol states that propofol has a 12-hour expiration time after being drawn up into a syringe; formulations of propofol without preservative may have a 6-hour expiration time after being drawn up into a syringe. ²⁸

How long can IV bags be spiked in advance of commencing use?

Recommendation: Anesthesia practitioners should minimize the time between spiking IV bags and patient administration; nevertheless, certain emergent or urgent circumstances may require advanced set-up of IV fluids and anesthesia providers should comply with their hospital protocols.

Following spiking of an IV bag, administration should commence as soon as possible. No specific time limit has been identified in the literature for advance preparation of IV bags. Rational: Facilities should determine whether local regulatory authorities (eg, state boards of health or pharmacy) have rules regarding spiking of IV bags. Scientific literature pertaining to spiking IV bags is sparse. Haas et al found no bacterial growth up to 8 hours in 80 bags of lactated Ringer’s solution spiked by a single provider following proper HH, but they did not address whether these results are replicable across multiple providers, in other settings, and with other types of IV solutions.

Anesthesia providers occasionally spike IV fluids in advance, especially in preoperative holding areas and in ORs that are reserved for emergencies. Providers should weigh the risks versus benefits of spiking IV bags that are not intended for immediate use. The authors encourage facilities to conduct a risk assessment in collaboration with their Infection Prevention and Control Departments.

Should syringes and medication vials be reused?

Recommendation: Single-dose medication vials and flushes should be used whenever possible. If multiple-dose medication vials must be used, they should be used for only 1 patient and should only be accessed with a new sterile syringe and new sterile needle for each entry. Syringes and needles are single patient devices and syringes should never be reused for another patient, even if the needle is changed.

Rationale: The CDC established safe injection practices as part of its 2007 Guidelines for Isolation Precautions: Preventing Transmission of Infectious Agents in Healthcare Settings. Numerous authorities and organizations, including the Association for Professionals in Infection Control and Epidemiology (APIC), AANA, ASA, and the Joint Commission have issued guidelines and/or recommendations concerning injection safety and have referenced CDC safe injection practices. The Association of Anaesthetists of Great Britain and Ireland has also issued safe injection practices that mirror those of the CDC. The CDC recommendations are based on reports of outbreaks of preventable healthcare-acquired viral and bacterial infections resulting from improper injection safety practices. Improper injection safety practices include: use of single-dose medication vials for multiple patients, improper use of multiple-dose vials, and use of a single syringe or needle to administer intravenous medication to multiple patients. Several groups of researchers have reported outbreaks of preventable healthcare-acquired viral and bacterial infections in inpatient operating suites, adult and pediatric medical-surgical wards, and outpatient endoscopy, surgery, infusion, myocardial perfusion testing, and pain centers.

How should keyboards and touch screens in the anesthesia work area be cleaned and protected from contamination?

Recommendation: Facilities should require cleaning and disinfection of computer keyboards and touchscreen computer monitors after each anesthesia case using a hospital-approved disinfectant consistent with manufacturers’ recommendations. Additionally, cleaning and disinfection should also occur every time there is obvious soiling or contamination of anesthesia work surfaces. Facilities should consider use of commercial plastic keyboard shields, sealed medical keyboards, or washable keyboards and touchscreens to facilitate thorough disinfection. Rational: The problem of bacterial contamination of clinical and OR equipment is well documented as a host of bacteria such as coagulase-negative staphylococci, Bacillus spp, and even MRSA inhabit anesthesia surfaces, such as workspace computer
touchescreens and keyboards.\textsuperscript{35} Research has identified the anesthesia computer mouse as one of the most contaminated surfaces in the OR, followed by the OR bed, nurse computer station mouse, the OR door, and the surfaces of the anesthesia medical work cart.\textsuperscript{36} Moist surfaces, such as damp gloves or computer keyboards, increase the risk of transmitting Staphylococcus epidermidis from one surface to another.\textsuperscript{61} Additional areas of concern include semi-sealed parts of anesthesia equipment, where bacteria may chronically colonize surfaces in areas not readily subject to cleaning procedures and where microbe growth may go undetected.\textsuperscript{61}

**What infection prevention and control modifications should be made, if any, for patients in contact isolation?**

**Recommendation:** Anesthesia providers should follow all institution-specific guidelines when caring for patients on contact isolation in the OR, including performing HH and using appropriate personal protective equipment (PPE). Environmental disinfection should follow recommendations regarding cleaning between cases, irrespective of an individual patient’s multidrug-resistant organism status.

**Rationale:** Data demonstrate that microorganisms, including multidrug-resistant organisms, can be spread via anesthesia providers in the OR. Research has shown contaminated hands of anesthesia providers contaminate the anesthesia work area, including the anesthesia machine, anesthesia cart, supplies on the cart, stopcocks and keyboards.\textsuperscript{23,34,62,63} In addition, up to 30% of organism transfer occurred between cases and was linked to an anesthesia work area that was not completely decontaminated with routine cleaning.\textsuperscript{34} The highest risk of contamination of the anesthesia work area occurs during induction and emergence of anesthesia.\textsuperscript{34,62} HH, contact precautions, and environmental disinfection recommendations to decrease transmission of pathogenic organisms outside of the OR also apply to providers in the OR environment.

**Implementation**

**Which techniques should be used to improve infection prevention practices by anesthesia providers?**

**Recommendation:** Facilities should conduct regular monitoring and evaluation of infection prevention practices. To promote adherence, improvement efforts should be collaborative and should include input from frontline anesthesia personnel and local champions. Hospital and physician leadership should identify clear expectations and goals, should ensure data transparency, and should facilitate use of process measures to improve performance.

**Rationale:** Although the authors did not identify studies that specifically addressed the efficacy of interventions to improve infection control among anesthesia providers, studies in anesthesia and elsewhere can inform an approach to implementing and sustaining improvements.

Improvement efforts should involve monitoring, evaluation, and feedback. Timely collection, analysis, and provision of data to providers are important, but they can be cumbersome and time consuming because collecting adherence data most often involves human observers. Overt observation of behaviors can improve practice,\textsuperscript{64} but it may be subject to the Hawthorne effect, in which the awareness of being observed changes one’s behavior.\textsuperscript{65,66} Covert observations have been successful using video observation of anesthesia practices,\textsuperscript{67,68} and procedural technique.\textsuperscript{59} Video recordings allow evaluation during all shifts and in many areas without overextending observing staff.\textsuperscript{67} Healthcare worker volunteers\textsuperscript{52} and nonprovider volunteers\textsuperscript{70} have assessed HH practices on inpatient units.

Facilities providing feedback should focus on ways to improve adherence rather than place blame. Researchers have found that providers fail to adhere to infection prevention practices not out of malice or indifference but due to a complex combination of beliefs, work environment, technology, information load, and conditioning.\textsuperscript{71–75} Audit and feedback programs have been shown to be effective when designed using both theory and evidence.\textsuperscript{76} Institutions should be mindful that the hierarchical nature of team organization in the anesthesia work area could hinder honest communication and feedback.\textsuperscript{77} Fostering psychological safety and comfort in taking interpersonal risk may help workplace team learning and improvement.\textsuperscript{78}

Clarity of expected behaviors in the context of a provider’s role can help focus educational activities.\textsuperscript{79} Interventions such as reminder cards or checklists have been utilized to improve adherence to transmission-based precautions,\textsuperscript{80,81} as has simulation for education and evaluation of different aspects of anesthesia practice.\textsuperscript{29,82–84} A Children’s Hospital Association working group developed an evaluation tool for infection prevention in anesthesia practice. While not validated empirically, facilities may consider use of this tool to initiate discussions among anesthesia providers and infection preventionists to identify areas of importance and in need of improvement.\textsuperscript{77}

Leadership support helps to define goals, remove barriers, and hold practitioners accountable for their performance.\textsuperscript{85} One institution demonstrated sustained improvements in HH adherence following a ‘stand-down’ event following a HH summit attended by hospital leaders. This involved a hospital-wide 15-minute period when all nonessential activity was stopped, plans to improve HH were discussed, and written action plans were submitted. Improvement efforts were supported by frequent covert observation and direct discussions of performance with institutional leaders.\textsuperscript{86} Although they are important to improving practices, institutions should be careful to not allow standards, monitoring, and incentives to have a negative effect on culture, learning, and interpersonal relationships.\textsuperscript{87}

**What is the impact of providing measurement and feedback data on HH?**

**Recommendation:** Facilities should monitor providers’ HH performance and give them feedback as part of a comprehensive program to improve and maintain adherence. Insufficient data exist to recommend the routine use of automated, electronic, or video monitoring and feedback, although examples in the literature demonstrate efficacy of such technology.

**Rationale:** Facilities have used various types of monitoring and feedback to increase providers’ adherence to HH. Because of the expense and the likelihood that measuring HH adherence through direct observation only provides a small sample of provider behavior, facilities’ interest in automated measurements has increased, including video surveillance\textsuperscript{88} and a variety of electronic devices that detect and record providers’ use of ABHR, to include such features as delivering real time reminders to perform
HH. Systematic reviews of studies conducted outside of the OR concluded that insufficient information exists to recommend the use of automated monitoring and feedback, although a study of personal, wearable ABHR dispensers that emitted an audible alarm 6 minutes after the previous activation of the dispensers reported a 27-fold increase in HH compared to standard fixed ABHR dispensers. An intermittent reminder to perform HH displayed on a video screen in the anesthesia work area increased the hourly frequency of HH by approximately 10-fold.

**What is the impact of providing measurement and feedback data on environmental disinfection?**

**Recommendation:** Facilities should utilize measures to assess the appropriateness and adequacy of environmental disinfection, track the measures, and share the results with stakeholders to optimize adherence to recommended disinfection practices.

**Rationale:** Measurement and feedback improve thoroughness of cleaning in inpatient settings via use of checklists of areas to clean, improvements to the cleaning methodology, including the cleanser used, and the use of visual indicators, such as ultraviolet visible markers and ATP bioluminescence. A study that focused on cross contamination of the work area by anesthesia providers reported improvements in anesthesia providers’ adherence following engagement by coaching, as viewed through remote video observation. Multiple studies have demonstrated improved cleaning after sharing monitoring data with environmental service (EVS) staff, along with education, observation, and collaboration between infection prevention and EVS personnel. Some facilities improved adherence through capital investment in EVS, most often through the creation of a dedicated environmental disinfection team.

The authors recognize that these short-term responses may not be sustainable or generalizable to all contexts, and we did not identify studies that measured how feedback alone affects environmental disinfection. Nonetheless, the literature suggests improvements to adherence derive from the belief among environmental services personnel that adequate cleaning protects the health of patients and families, is expected, and is supported by the facility.

**Background**

**Evidence for infectious sources in the anesthesia work area**

A growing body of literature suggests that the anesthesia work area can become contaminated with pathogens. Hall confirmed the presence of blood contamination on 33% of surfaces that have direct contact with the patient (eg, blood pressure cuffs and pulse oximeter probes), and found that visual inspection of anesthesia work area surfaces was insensitive for detecting it. In 2001, Miller et al reported the presence of proteinaceous material, even after cleaning, on most laryngeal masks and laryngoscope blades. Maslyk et al identified a significant environmental bioburden with both commensal and pathogenic bacteria, including coagulase-negative Staphylococcus, Bacillus spp, Streptococcus, S. aureus, Acinetobacter and other gram-negative bacilli. With providers’ use of double gloves for airway management, contamination of the anesthesia work area decreased but was not eliminated. Fukada et al reported significant contamination of the computer keyboard in the OR with commensals and pathogens such as S. aureus and MRSA due to anesthesia provider HH practice.

The intraoperative environment poses a threat for clinically significant bacterial cross transmission. Loftus et al studied the impact of bacterial contamination of patients, providers’ hands, and the environment on stopcock contamination in the OR. Providers’ hands and, in particular, the surrounding environment, were important drivers of stopcock cross transmission, which was associated with increased patient 30-day mortality. In a subsequent study, Loftus et al demonstrated that bacterial transmission in the OR anesthesia work area was associated with 30-day postoperative infections, impacting as many as 16% of patients undergoing surgery. Loftus et al found anesthesia provider hand contamination was a proximal source of both enterococcal and staphylococcal transmission in the anesthesia work area. Birnbach et al reported a high degree of fluorescent marker spread following simulated airway management, including fluorescence on the face of a mannequin, the IV hub, and the keyboard, highlighting the potential for bacterial cross-transmission during anesthesia care.

A host of bacteria such as coagulase-negative staphylococci, Bacillus spp, and MRSA inhabit the anesthesia work area, including computer touchscreens and keyboards. The anesthesia computer mouse is one of the most contaminated surfaces in the OR, followed by the OR bed, nurse computer station mouse, the OR door, and the surfaces of the anesthesia medical work cart. Moist surfaces, such as damp gloves or computer keyboards, increase the risk of transmitting S. epidermidis from one surface to another. Additional areas of concern include semi-sealed parts of anesthesia equipment and areas not readily subject to cleaning procedures, where bacteria may chronically colonize surfaces and microbial growth may go undetected.

Medications used in anesthesia practice can become contaminated during use and support the growth of microorganisms, including bacteria and fungi. Mahida et al assessed the frequency of bacterial contamination of intravenous fluids and medications used in a sample from 101 surgical procedures performed at a single center. Of 426 used medication syringes (median, 4 per case), 15% of syringe tips and 4% of syringe contents grew bacteria, predominantly low colony counts of skin organisms (coagulase-negative Staphylococcus spp, Micrococcus, and Kocuria). Contamination of syringe contents was significantly more common during emergency than elective surgical procedures (odds ratio, 4.50; P = .01). The authors did not compare the frequency of medication administration or HH practices between emergency and elective procedures. As noted previously, Gargiulo et al found bacterial growth in 10 of 197 syringes (5%), 5 of 17 needles (35%), and 5 of 38 IV fluid bags (13%) into which medications were injected, and gram-positive bacteria were most commonly isolated. The investigators observed that HH was never performed before entry into the simulation center or before drawing up medications, and that the septa of medication vials and IV injection ports were never disinfected with alcohol before they were used. They also observed nonsterile equipment, including stethoscopes and medical records, placed on top of uncapped, in-use medication syringes, but these researchers did not report the frequency with which it was observed. Although the literature search for this guidance did not identify a study that compares the impact of capping versus noncapping syringes used to administer multiple doses of medication on the frequency of bacterial contamination in simulation.
settings or clinical anesthesia practice, this same group of investigators found similar results in a follow-up study of actual patients in ORs.29

A 1999 outbreak of Serratia marcescens among 7 postoperative patients was linked to a single anesthesiologist who drew up multiple propofol syringes at a time and did not use gloves for drawing up the syringes or for intubations.108 Behaviors cited during observations of other anesthesia personnel in this center included preparing multiple syringes of propofol at one time, using a single syringe for drawing up doses for different patients, using a single vial of propofol during a period of >6 hours and for more than a single patient, lack of compliance with glove usage, and failing to disinfect the rubber stopper of the medication vial before use.

Hilliard et al109 investigated flip-top drug vials and confirmed that the surface of the stopper of flip-top vials is frequently not sterile. Although this was an expected finding because stoppers of flip-top vials are not designed to be sterile and should be scrubbed with alcohol prior to access, in a survey of 878 anesthesiologists, 52% of respondents believed that the vial stoppers were sterile under the flip-top caps.109 A survey performed among anesthesia providers in New Zealand found that almost 80% of respondents said they rarely or never wiped the intravenous line injection port with alcohol before injection. Furthermore, 54% of anesthesia providers failed to wipe the multi-dose vial septum with alcohol before use.110

Evidence for Infection Prevention Measures in the Anesthesia Work Area

Hand hygiene

Epidemiology studies suggest that improved intraoperative HH is an important component of intraoperative infection prevention in the OR.111 The indications for the WHO 5 Moments include before and after direct contact with patients, after contact with body fluids or mucous membranes (eg, during endotracheal intubation), and after removal of gloves.112 Several studies have assessed opportunities for and compliance with the WHO 5 Moments recommendations during the provision of anesthesia care.2,3,113,114 Biddle et al13 performed an observational study of the HH of anesthesia providers using trained observers impersonating nurses to quantify HH practices during anesthesia delivery while minimizing the potential for observer influence. The overall failure to perform HH for all providers was 82%. They found that during certain cases (eg, extensive blood loss, patients with particularly challenging airway issues, periods of high task density such as complicated emergence from anesthesia, and others) HH indications according to WHO reached 54 per hour.

Muñoz-Price et al found that anesthesia providers performed only 13 HH events in 8 hours of observation. A subsequent study by Muñoz-Price et al reported that placing an ABHR dispenser on the anesthesia machine, in addition to standard wall-mounted dispensers, increased the rate of HH events from 0.5 to 0.8 events per hour (p = 0.01).4 ABHRs are able to achieve a ~4-log (99.99%) reduction in microorganisms on providers’ hands after a single application.115 Petty5 suggests routine use of wearable ABHR dispenser to improve HH compliance among anesthesia staff. Koff et al6 studied wearable ABHR dispensers. During the control period, providers performed HH using either a wall-mounted ABHR dispenser within 3 steps of the anesthesia work area or an ABHR dispenser on the anesthesia cart, and observers recorded the frequency of HH events. The intervention consisted of the use of personal, wearable ABHR dispensers with an audible reminder that alerted the provider if ABHR use had not occurred for 6 minutes. The personal, wearable device increased the frequency of ABHR use from 0.15 to 7.1 events per hour for attending physicians (P = 0.008) and from 0.38 to 8.7 events per hour for other providers (P = 0.002). The increase in HH was associated with reduction in contamination of the anesthesia work area and peripheral intravascular tubing. HAI rates decreased from 17.2% to 3.8% (P = 0.02). Notably, when the same group of investigators attempted to replicate their own results in a larger, multicenter study, use of the wearable dispensers was associated with an increased frequency of HH but not with a reduction in HAIs.7 Wearable dispensers were also associated with a reduction in ventilator-associated pneumonia in the ICU.116

Anesthesia providers in the OR are vulnerable to acquiring transient pathogenic microorganisms from hand contact with excretions, saliva, blood, or urine of hospitalized patients, and becoming vectors to transmit these organisms to others by direct touch.3,8,117 Gloves currently represent the most common barrier to prevent contamination and colonization of providers’ hands during patient contact, but they require frequent changes during the anesthesia workday and HH after each removal.

The ASA Recommendations for Infection Control for the Practice of Anesthesiology, 3rd edition, explicitly state that gloves should be worn whenever in contact with blood, body fluids, mucous membranes, or nonintact skin, and that gloves are not intended for reuse because removal of microorganisms and integrity cannot be ensured.47 Any time gloves are contaminated they should be removed and appropriate HH performed. In addition, the AANA Guidelines state that gloves should not be used with >1 patient.46

Injection of intravenous drugs

Peripheral intravenous tubing stopcocks and injection ports that are used for medication administration frequently become contaminated with bacteria during intraoperative use. Bacterial contamination was detected in >30% of intraluminal surface samples of stopcocks cultured at the end of general anesthesia cases,22,23 and included common skin contaminants (eg, coagulase-negative staphylococci, Micrococcus) as well as multidrug-resistant organisms (eg, MRSA, vancomycin-resistant enterococcus, Acinetobacter). Several potential reservoirs within the OR have been associated with intravenous tubing stopcock contamination.

Anesthesia providers report low overall rates of compliance with national recommended practices for injection port disinfection. Only 20.9% of New Zealand anesthetists reported “always” or “frequently” wiping the IV line with alcohol before injection in the OR although 31.6% responded “never” to this question.110 Similarly, 40% of anesthesia service managers in Australia reported “never disinfecting” arterial line access ports with 70% alcohol or povidone iodine before use.118

In a prospective observational study of 548 adult patients undergoing surgery requiring general anesthesia, Loftus et al33 found that 23% of stopcock samples became contaminated intraoperatively. Stopcock contamination was more often attributed to bacterial strains contaminating the anesthesia machine’s adjustable pressure-limiting valve than to strains on anesthesia providers’ hands or colonizing the patient’s nasopharynx and axilla. Bacterial contamination rates of IV tubing stopcock
extensions were similar after 6 hours of incubation following removal at the end of procedures. Intraoperative stopcock contamination was associated with a lower hourly rate of HH compliance by anesthesia providers resulting in increased risk of 30-day mortality for patients but not with increased risk of postoperative HAI s. The article did not report the method and frequency of stopcock hub disinfection or medication injection practices.

In a prospective study of same-day ambulatory surgery procedures, bacterial contamination rates of IV tubing stopcock extension sets were similar after 6 hours of incubation following removal at the end of procedures performed with (17.3%) and without (18.6%) administration of ethylenediaminetetraacetic acid (EDTA)–containing propofol anesthetic. Procedures with propofol anesthesia were longer (1–2 hours versus <1 hour) and associated with a greater number of administered medications and hub interactions than nonpropofol procedures. When IV extension set sampling was repeated after 24 hours and 48 hours hold time, presence of visible propofol in the dead spaces of stopcocks was associated with a significant increase in bacterial colony counts compared with the extension set with no visible propofol or sets with no use of propofol, suggesting that even preservative-containing propofol may promote bacterial growth in IV stopcock and tubing associated with prolonged durations of administration. The authors did not report compliance with stopcock injection port disinfection or provider intraoperative HH.

In a prospective, single-blinded controlled trial at a single center, Loftus et al. randomized 592 ORs to use either conventional open stopcocks or conventional open stopcocks that were disinfected with an alcohol containing scrub device. Disinfection of the open stopcocks significantly reduced bacterial contamination of the stopcock lumen (32% vs 41%; adjusted odds ratio, 0.703; P = .047); however, the rate of contamination was high in both groups. More than half the bacterial isolates identified in stopcock lumens or aspirated lumen effluent were coagulase-negative staphylococci (52%), S. aureus (1%), Pseudomonas aeruginosa (1%), and other gram-negative bacilli (1%).

In another prospective, single-blinded controlled trial at the same center, Loftus et al. randomized 468 ORs and anesthesia providers to 1 of 3 medication injection schemes: (1) a closed stopcock device that was disinfected with 70% isopropyl alcohol before injection, (2) the same closed stopcock device not disinfected before injection, and (3) usual practice with conventional open-lumen stopcocks. The port disinfection arm required the use of 70% alcohol for disinfection and 30 seconds drying between each injection, but the study did not control for the technique (scrubbing vs wiping) or alcohol source (pump dispenser vs pad). Following induction of anesthesia, the rate of bacterial contamination of the closed stopcock with alcohol disinfection was 0%, while the closed stopcock device with no disinfection before injection was 4%, and the open stopcock system was 3.2%, suggesting that the benefit of a closed stopcock device derives primarily from the ability to disinfect the injection port prior to drug injection.

In a quasi-experimental quality improvement project at a pediatric teaching hospital, Martin et al. assessed the impact of a bundle of interventions on reducing rates of CLABSI among patients that travelled out of the ICU for anesthesiology care in ORs or procedure areas. The intervention included recommendations and anesthesia provider education to limit touch contamination during airway management, peripheral IV insertion, and anesthesia cart contact. In addition, providers were instructed to perform a single 15-second scrub with alcohol and 15-second drying time of the IV injection ports at the start of each case before attaching medication syringes to the series of 3-way stopcocks. All medications administered via this stopcock set were considered clean, although the study does not report provider HH before medication administration. CLABSI rates decreased from a baseline of 14.1 per 100 trips from the ICU to 9.7 in year 1 and to zero in year 2. During this same period, hospital-wide CLABSI rates decreased from 3.5 to 2.2 per 1,000 device days, suggesting that other interventions outside of modifications in anesthesia practice likely contributed to the observed reduction in CLABSI rates among ICU patients who received anesthesia care.

Cole et al. cultured stopcocks used for propofol and nonpropofol anesthesia. Bacteria were recovered from 26 of 150 propofol anesthesia stopcocks (17.3%) and 28 of 150 non-propofol stopcocks (18.6%). As expected, mean bacterial colony counts were much higher at 24 hours for propofol stopcocks, whether or not propofol was visible (nonpropofol 95 colony-forming units [CFU]/mL, nonvisible propofol 418 CFU/mL, visible propofol 2,361 CFU/mL), suggesting that safe injection practices may not consistently occur.

Environmental cleaning

The bioburden of the anesthesia work area and potential cross-transmission dynamics pose a threat to patient safety. Practices for the cleaning, handling, and processing of anesthesia equipment have been published by the Association of Perioperative Registered Nurses (AORN). Martin et al. reported a significant reduction of CLABSI s by improving practices in the OR including HH, strategic gloving, and standardized cleaning of the anesthesia cart, IV pole, stopcock clamp, anesthesia machine, computer, monitor, knobs, surfaces, and laryngoscope handle.

Clark et al. trained a group of anesthesia providers to keep the anesthesia equipment cart clean, placed a placard on the cart top stating “clean hands only,” designated the surface of the anesthesia machine for materials used during the case, and placed a separate container on the anesthesia machine for contaminated items. Known contaminated sites were wiped with an ammonium chloride-based wipe. After enacting these interventions, colony counts substantially declined on the adjustable pressure limiting valve, the oxygen control knob, the anesthetic agent control dial, and drawer pulls to the first and second drawers in the anesthesia equipment cart.

Although several studies identified by the literature search demonstrated contamination of anesthesia equipment and workspaces, as well as possible transmission of a variety of microorganisms within the anesthesia environment, the search did not identify studies that evaluated the impact of equipment covers on the level of environmental contamination or on risk of patient infection. Maslyk et al. swabbed anesthesia machine tabletops located in randomly selected ORs and detected Acinetobacter and other gram-negative bacilli, S. aureus, and coagulase-negative staphylococci, both before and after devices were used, despite routine cleaning. Baillie et al. obtained swabs from surfaces of anesthetic and monitoring equipment that were not in contact with patients but were routinely touched by anesthesia providers during surgical procedures, including oxygen, nitrous oxide and air flow control knobs, vaporizer dials,
breathing system bags, adjustable pressure-limiting valves, and monitoring control buttons. They detected the same types of bacteria as Maslyk et al.

Loftus et al assessed transmission of potentially pathogenic bacteria in the anesthesia work area by culturing intravenous stopcock sets and adjustable pressure-limiting valve complex and agent dials prior to the start of surgical procedures and after completion of the case. They noted a significant increase in the number of bacterial colonies per surface area sampled at case conclusion and found bacterial contamination of intravenous stopcock sets in 32% of cases, as well as an association between the risk of stopcock contamination and degree of anesthesia work space contamination. In a series of follow-up studies, they evaluated the dynamics of transmission of enterococci, *S. aureus*, and gram-negative organisms by comparing isolates found on patient screening cultures, anesthesia providers’ hands, and the adjustable pressure-limiting valves and agent dials of the anesthesia machines during the first and second operative cases (case pairs) performed on a given day at 3 academic medical centers. Isolate relatedness was based on species, antimicrobial susceptibility results, and temporal association. For all 3 organism types, possible transmission events were common and appeared to involve both environmental and anesthesia provider hand contamination reservoirs. Mahida et al performed swab cultures of the external surface of syringe tips and syringe contents in addition to surface swabs of ventilator machines and found that the same bacterial species was cultured from both the ventilator and the syringe tip in 13% of cases, as well as in the intravenous fluid administration set in 4% of cases, suggesting the potential for environmental contamination leading to contamination of intravenous administered medications.

Gonzalez et al compared different disinfectant wipes, finding *S. aureus*, Bacillus atrophaeus spores, and Clostridium sporogenes spores on the surface of an anesthesia machine, sterile flat caps, and ridged caps (used to simulate the actual knobs on anesthesia machines) and cleaned with 5 commercially available disinfectant wipes containing: (1) diisobutylphenoxyethoxyethyl dimethyl benzyl ammonium chloride, (2) citric acid, (3) sodium hypochlorite, (4) hydrogen peroxide, and (5) o-phenylphenol/o-benzyl-p-chlorophenol as well as sterile gauze soaked in water or 5% bleach diluted 1:10 in water. All wipes cleaned the surfaces significantly better than the no-wipe control. Removal of *S. aureus* from the machine surface by the commercial wipes was not better than gauze with bleach and water but outperformed gauze and water when cleaning the flat and ridged caps. Bacillus atrophaeus and C. sporogenes spores were more difficult to clean from the machine surface and caps compared to *S. aureus*. Gauze with bleach and water removed 99% of spores from the machine’s surface, and only the sodium hypochlorite wipe significantly outperformed gauze and bleach and water. No commercial disinfectant wipe performed significantly better than gauze and bleach water when cleaning spores from the caps. Gonzalez et al found that all 3 organism types maintained viability after being dried on these surfaces after a month. The investigators concluded that these results emphasized the importance of physical removal of bacteria from anesthesia device surfaces between uses.

Rutala et al found that novel touchless disinfection technologies (eg, ultraviolet-C light and hydrogen peroxide cleaning systems) are effective in further reducing bioburden after a standard cleaning and may be considered by facilities for terminal cleaning of ORs. However, the clinical efficacy on reduction of device-associated infections and SSIs has not been studied, and the intervention has not been subjected to a cost–benefit analysis.

**Airway management**

Although few articles have been published reporting outbreaks directly linked to contaminated laryngoscopes, multiple studies have demonstrated the high frequency with which blood and bacteria can be found on both laryngoscope blades and handles, even after reprocessing. One study found viable bacterial contamination in up to 57% of blades and 86% of handles from laryngoscopes that were disinfected and ready for use on the next patient. Bhatt et al also found bacterial contamination of flexible fiber-optic laryngoscopes. Several studies have noted the theoretical risk of transmitting Creutzfeldt-Jakob Disease (CJD) from contaminated reusable laryngoscopes. CJD proteins have been identified in lymphoid tissue from patients with variant CJD (vCJD) but not other prion diseases, and Hirsch et al found that 30% of laryngoscope blades contained lymphocytes after a single use. Although there are no published reports of prion transmission via laryngoscopy, the long latency period between exposure and onset of disease makes identification of transmissions difficult. Based on the potential, though unproven, risk of vCJD transmission and the extreme difficulty of eradicating prion proteins from equipment, the authors suggest that facilities consider single-use laryngoscope blades.

The literature search identified a number of studies that compare the cost and function of single-use laryngoscopes or video-laryngoscopes, but no studies were identified that used clinical infection outcomes. Using direct patient care and simulated patient studies, the search identified >30 articles that compared devices based largely on indirect patient related outcomes, such as user experience, ease of visualization of larynx during intubation, efficiency of use during rapid sequence intubation, duration of laryngoscopy, peak force applied to tissues, and quality of light. The various studies compared different products and used different outcomes. Overall providers showed a preference toward reusable direct laryngoscopes/video-laryngoscopes over the single-use devices; however, older studies do not reflect the current state of single-use laryngoscope technology.

The authors identified unpublished, anecdotal reports from a number of hospitals that switched from reusable to single-use laryngoscopes. These facilities cited lower cost of new generation single-use laryngoscopes compared to previously tested models, especially when the cost of high-level disinfection or sterilization of reusable laryngoscope handles was included. Additionally, the function of single-use laryngoscopes was reportedly improved compared to earlier models and compared favorably with reusable equipment, especially considering that reusable laryngoscope function may degrade over time due to wear and tear. In addition, single-use laryngoscope batteries hypothetically are fresh, whereas reusable laryngoscope batteries discharge variably with repeated use.

Anesthesia providers’ hands may become contaminated with upper-airway secretions while providing airway management and endotracheal intubation resulting in cross contamination of the anesthetizing area. Two studies were identified in the literature search related to “double gloving” during airway management. In these studies, conducted in a simulation setting, a
Future Directions

The authors identified several unique elements of anesthesia practice that pose unsolved problems for infection prevention. These include the anesthesia machine, the anesthesia cart, and provider prepared drugs and IV infusion bags.

Numerous challenges exist for thorough cleaning of the anesthesia machine between cases. The anesthesia machine is a complicated apparatus with an irregular and complex external surface. Many anesthesia machines also have drawers to store supplies. Anesthesia machines were designed at a time when the importance of infection prevention in the anesthesia workplace was not well understood, and since then, the fundamental design has not changed greatly. The anesthesia machine may need to undergo fundamental redesign that allows for quick and effective cleaning of the external surfaces.

The anesthesia supply cart presents similar challenges and cleaning the anesthesia cart between cases can be extremely challenging depending upon the particular design of the cart. Anesthesia carts have many variations, which also can have a complex exterior surface due to attachment of electrical components such as a defibrillator or cardiac output monitor, sharps collection containers, waste bins, and discarded drug collection containers. Supplies and materials may be stored in cart drawers but also in bins on the top of the cart. Typical anesthesia carts contain supplies and materials intended to be used for numerous cases. Contamination of supplies can occur if providers do not remove soiled exam gloves and apply ABHR prior to obtaining supplies and materials from storage. Few examples exist of practices that have attempted to include the anesthesia cart in a “clean zone,” where only clean hands are allowed. Although some success has been documented with this approach, maintaining the desired provider behavior presents challenges.

Anesthesia providers are frequently engaged in preparing sterile drugs for injection by bolus and infusion. Provider prepared drugs are not prepared using the same stringent methods as pharmacies and commercial compounders, increasing the possibility for contamination. Because bacteria may multiply over time, common sense suggests that providers should commence administration of provider prepared drugs promptly; however, little evidence exists concerning the length of time that is safe. Minimizing the use of provider-prepared drugs by using drugs that are prepared in a pharmacy or by a commercial compounding is a possible or partial solution. Some of the recommendations provided in this guidance might need to be reinterpreted if a new version of USP 79728 is available (scheduled for release in late 2019).

The authors encourage investment in research to better understand the infection prevention and control problems posed by the anesthesia work station and to develop design improvements that reduce the risk of infection.

Acknowledgments. The authors thank Randall M. Clark, MD, Chair, American Society of Anesthesiologists (ASA) Section on Clinical Care, Denver, Colorado, for extensively reviewing and vetting the guidance, as well as review and feedback by ASA workgroup members: Lois A. Connolly, MD, Chair, ASA Committee on Quality Management and Departmental Administration, Waukesha, Wisconsin; Elizabeth Rebello, MD, US Pharmacopeia Representative, ASA Committee on Quality Management and Departmental Administration, Houston, TX; Mary Ann Vann, MD, Chair, ASA Committee on Occupational Health, Medfield, MA; Richard A. Beers, MD, Advisory Group on Infectious Disease, ASA Committee on Occupational Health, Syracuse, NY; Matthew T. Pennovich, PhD, Director of Quality and Regulatory Affairs, ASA, Washington, DC. The authors thank Charles Grifis, PhD, CRNA, Lynn Reede, DNP, MBA, CRNA, and Victoria Hledin, MPH, who reviewed the document on behalf of the American Association of Nurse Anesthetists (AANA). The authors thank Susan A. Dolan, RN, MS, CIC, Hospital Epidemiologist at the Children’s Hospital Colorado, Colorado Springs, Colorado, for serving as an expert reviewer of the guidance. The authors thank Valerie Deloney, MBA, for her organizational expertise and assistance in the development of this manuscript.

Financial support. This expert guidance was supported in part by the SHEA Research Network (SRN).

Conflicts of interest. The following disclosures reflect what has been reported to SHEA. To provide thorough transparency, SHEA requires full disclosure of all relationships, regardless of relevancy to the guideline topic. Evaluation of such relationships as potential conflicts of interest is determined by a review process which includes assessment by the SHEA Guidelines Chair, the SHEA Conflict of Interest Committee, and may include the Board of Trustees and Editor of Infection Control and Hospital Epidemiology. The assessment of disclosed relationships for possible COI is based on the relative weight of the financial relationship (ie, monetary amount) and the relevance of the relationship (ie, the degree to which an association might reasonably be interpreted by an independent observer as related to the topic or recommendation of consideration). The reader of this guidance should be mindful of this when reviewing the list of disclosures.

D.B. reports activity with APSF (Board of Directors) and Anesthesia and Analgesia (A&A) Editorial Board. R.M. reports research grants/contracts with Medimmmune, Johns Hopkins (lead in multicenter trial) HA1 Among Surgical & ICU Patients. B.C. reports research grants/contracts with Pfizer, Merck, CDC, Preventing Hemodialysis Related BSI. E.P.D. reports research grants/contracts with Tetraphase, A Phase 3 Randomized Double-Blind Double-Dummy Multicenter Prospective Study to Assess the Efficacy & Safety of Etravirine vs Efavirenz Intra-Abdominal Infections, advisory consultant roles with Merck, Baxter, Ortho-McNeil, Tangarra, Schering-Plough, Astellas, CareFusion, Durata, Pfizer, Rib-X, institutional benefit with ExoXemis, UW letter to FDA supporting research proposal <$10,000, activities with SIS (Board Member), ICHE (Editorial Board), CDC/HICPAC (content expert for SSI guideline), SCIP. G.H.P. reports research grants/contracts with UT, Decreasing Vancomycin Use in the NICU. B.L.J. reports research grants/contracts with Gilead Sciences Inc., A Multicenter Randomized Double-Blind Double-Dummy Phase 3 Study of the Safety & Efficacy of Ritonavir-Boosted Elvitegravir (EVGr) vs. Raltegravir (RAL) Administered with a Background Regimen in HIV-1 Infected, Antiretroviral Treatment-expe, CHUM, The Canadian Cohort of Slow Progressors (HIV), Pfizer Canada, An International Multicenter Prospective Observational Study of the Safety of Maraviroc Used with Optimized Background Therapy in Treatment-experienced HIV-1 Infected Patients, Ottawa Hospital, A Randomized Controlled Clinical Trial of Micronutrient & Antioxidant Supplementation in Persons with Untreated HIV Infection, MAINTAIN Study CTN 238 & CTN 254: Inflammatory Markers Sub-Study, Canadian HIV Trials Network, VALIDATE, Capital Health Research FundFrailty in people living with HIV, PHAC CNISP: Surveillance for HA-CVC-BSI, CDI, PJI (hip & knee), VP shunt infection, MRSA, VRE, & CRE, and institutional benefit through Pfizer Canada, GSK, Sunovion Pharmaceuticals Canada (unrestricted

fluorescent marker identified the hypothetical spread of material from the patient’s airway to the surrounding environment. Wearing double gloves and immediately discarding the outer gloves following airway management led to reduction in contamination of the environment. Contamination was further reduced when the laryngoscope was “sheathed” with an outer glove as it was removed.
grant), Capital District Health Authority Foundation, Infectious Diseases CME for Family Physicians (October 2013), < $10,000, Optimer Pharmaceuticals Canada, Merck Canada, ViVi Health Canada, BMS Canada, Gilead Sciences (unrestricted grant), Atlantic Canada HIV Education (September 2012), > $25,000, and activity with PHAC Working Group for IC (Chair of Guidelines for HCW Infected with a Bloodborne Pathogen), CJI/DMM (Associate Editor), IDSA (influenza guideline panel, SHEA), CPSNS (Chair), ad hoc Committee on BBP. D.P. reports activity with Extended National Faculty (SHEA faculty stipend for HRET/AHA CUSP). R.P.T. reports activity with APSF (Board of Directors) and Anesthesia and Analgesia (A&A) Editorial Board. All other authors report nothing to disclose.

Supplementary material. To view supplementary material for this article, please visit https://doi.org/10.1017/ice.2018.303

References


14. Guidance on personal protective equipment (PPE) to be used by healthcare workers during management of patients with confirmed ebola or persons under investigation (PUIs) for ebola who are clinically unstable or have bleeding, vomiting, or diarrhea in US hospitals, including procedures for donning and doffing PPE 2015. Centers for Disease Control and Prevention website. https://www.cdc.gov/vhf/ebola/health-care-us/ppe/guidance.html. Published 2015. Accessed October 25, 2018.


44. AANA. Safe Injection Guidelines for Needle and Syringe Use. 2014.


51. AANA. Safe Injection Guidelines for Needle and Syringe Use. 2014.


62. AANA. Safe Injection Guidelines for Needle and Syringe Use. 2014.


64. AANA. Safe Injection Guidelines for Needle and Syringe Use. 2014.

65. AANA. Safe Injection Guidelines for Needle and Syringe Use. 2014.

66. AANA. Safe Injection Guidelines for Needle and Syringe Use. 2014.

67. AANA. Safe Injection Guidelines for Needle and Syringe Use. 2014.

68. AANA. Safe Injection Guidelines for Needle and Syringe Use. 2014.

69. AANA. Safe Injection Guidelines for Needle and Syringe Use. 2014.

70. AANA. Safe Injection Guidelines for Needle and Syringe Use. 2014.

71. AANA. Safe Injection Guidelines for Needle and Syringe Use. 2014.

72. AANA. Safe Injection Guidelines for Needle and Syringe Use. 2014.

73. AANA. Safe Injection Guidelines for Needle and Syringe Use. 2014.

74. AANA. Safe Injection Guidelines for Needle and Syringe Use. 2014.

75. AANA. Safe Injection Guidelines for Needle and Syringe Use. 2014.

76. AANA. Safe Injection Guidelines for Needle and Syringe Use. 2014.

77. AANA. Safe Injection Guidelines for Needle and Syringe Use. 2014.

78. AANA. Safe Injection Guidelines for Needle and Syringe Use. 2014.

79. AANA. Safe Injection Guidelines for Needle and Syringe Use. 2014.

80. AANA. Safe Injection Guidelines for Needle and Syringe Use. 2014.

81. AANA. Safe Injection Guidelines for Needle and Syringe Use. 2014.

82. AANA. Safe Injection Guidelines for Needle and Syringe Use. 2014.

83. AANA. Safe Injection Guidelines for Needle and Syringe Use. 2014.

84. AANA. Safe Injection Guidelines for Needle and Syringe Use. 2014.

85. AANA. Safe Injection Guidelines for Needle and Syringe Use. 2014.

86. AANA. Safe Injection Guidelines for Needle and Syringe Use. 2014.

87. AANA. Safe Injection Guidelines for Needle and Syringe Use. 2014.

88. AANA. Safe Injection Guidelines for Needle and Syringe Use. 2014.

89. AANA. Safe Injection Guidelines for Needle and Syringe Use. 2014.

90. AANA. Safe Injection Guidelines for Needle and Syringe Use. 2014.

91. AANA. Safe Injection Guidelines for Needle and Syringe Use. 2014.

92. AANA. Safe Injection Guidelines for Needle and Syringe Use. 2014.

93. AANA. Safe Injection Guidelines for Needle and Syringe Use. 2014.

94. AANA. Safe Injection Guidelines for Needle and Syringe Use. 2014.

95. AANA. Safe Injection Guidelines for Needle and Syringe Use. 2014.

96. AANA. Safe Injection Guidelines for Needle and Syringe Use. 2014.

97. AANA. Safe Injection Guidelines for Needle and Syringe Use. 2014.

98. AANA. Safe Injection Guidelines for Needle and Syringe Use. 2014.


100. AANA. Safe Injection Guidelines for Needle and Syringe Use. 2014.

101. AANA. Safe Injection Guidelines for Needle and Syringe Use. 2014.

102. AANA. Safe Injection Guidelines for Needle and Syringe Use. 2014.

103. AANA. Safe Injection Guidelines for Needle and Syringe Use. 2014.

104. AANA. Safe Injection Guidelines for Needle and Syringe Use. 2014.

105. AANA. Safe Injection Guidelines for Needle and Syringe Use. 2014.

106. AANA. Safe Injection Guidelines for Needle and Syringe Use. 2014.

107. AANA. Safe Injection Guidelines for Needle and Syringe Use. 2014.

108. AANA. Safe Injection Guidelines for Needle and Syringe Use. 2014.


110. AANA. Safe Injection Guidelines for Needle and Syringe Use. 2014.

111. AANA. Safe Injection Guidelines for Needle and Syringe Use. 2014.

112. AANA. Safe Injection Guidelines for Needle and Syringe Use. 2014.


